AbbVie remains strong long-term performer, offering a solid dividend yield and robust revenue growth despite share price dips ...

AbbVie is deploying more capital into its pipeline, which features 50 programs in mid- and late-stage development and over 375 clinical trials. See why ABBV stock is a Buy.

ABBV's $2.1 billion Capstan deal and 20+ recent acquisitions sharpen its pipeline edge across immunology and beyond.

AbbVie has announced a definitive agreement to acquire Capstan Therapeutics, a clinical-stage biotechnology company, for up ...

Half of the year is over! So, which pharmaceutical giant outpaces the others? Sharp investors wonder whose market ...

This acquisition will allow AbbVie access to Capstan’s lead asset, CPTX2309, a potential first-in-class therapy currently in Phase 1 development for B cell-mediated autoimmune diseases.

AbbVie announced a $2.1 billion deal to acquire Capstan Therapeutics, strengthening its cell therapy and immunology portfolio (5). Meanwhile, Eli Lilly acquired Verve Therapeutics, whose VERVE-102 ...

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

The pharma began its outreach to the HS community well before securing Bimzelx’s approval in the indication. In the spring of ...